Bio-Techne Corporation has made several noteworthy advances and strategic decisions recently. They have unveiled a
next-generation high throughput Simple Western system and made a
strategic investment in Spear Bio. However, there have been some challenges as well, such as a decrease in stake by an insider by 19% and several stakeholders altering their positions such as Tidal Investments LLC, PEAK6 Investments LLC, and Shell Asset Management Co. Interestingly, Bio-Techne’s stock appears undervalued as its shares could potentially be 32% above their intrinsic value estimate. They have made significant innovations with over
10,000 peer-reviewed publications citing their RNAscope technology and have recently showcased their
MauriceFlex™ system at the annual ASMC conference. They were recently awarded for their innovations in the field of spatial biology by CiteAb. There have been mixed views on their earnings performance with a couple of quarters having missed their estimates. They have also
formed partnerships with Nikon Instruments, Novomol-Dx, and expanded their bio-tech offerings with the
acquisition of Lunaphore.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Fri, 02 Aug 2024 16:00:31 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 2
